Perioperative Insulin Glargine Dosing Study
Information source: William Beaumont Hospitals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes; Surgery
Intervention: Lantus (Drug); Insulin (Other); Lantus (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Tamra Dukatz Official(s) and/or principal investigator(s):
Tamra Dukatz, MSN, CRNA, Principal Investigator, Affiliation: William Beaumont Hospitals
Summary
The main objective of this study is to compare three strategies of evening insulin glargine
dosing to preoperative glucose values in patients with diabetes undergoing surgery to
determine which dosing strategies most often achieves the admission target study values of
100-179 mg/dl.
Clinical Details
Official title: A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery
Detailed description:
There are no evidence-based guidelines for insulin glargine (Lantus) dosing in the
perioperative setting. Insulin glargine provides peakless 24-hour coverage of basal insulin
needs for people with both Type 1 and Type 2 diabetes. Insulin glargine may be used as the
sole insulin or in combination with other rapid-acting insulin to achieve glycemic control.
Anesthesia literature recommends that blood sugar values on insulin-dependent patients be
maintained between 120-180 mg/dl in most surgeries. Symptoms of low blood sugar are
undetectable in anesthetized patients, and blood glucose is tested at least hourly. Since
patients are still awake and alert toward hypoglycemic symptoms in the preoperative area,
the admission target study values are 100-179 mg/dl. Glucose values greater than 200 mg/dl
have been associated with increased rates of infection, and exacerbated complications if a
major cardiovascular event happens.
Frequently insulin glargine is administered in the evening. Patients who are scheduled for
surgery in the morning are asked not to eat or drink after midnight. Some endocrinology
experts recommend that all or part of the patient's usual insulin glargine should be given
to avoid high blood sugar; however, whenever insulin is given without food, the possibility
of low blood sugar exists.
1. Patients in Group 1 will administer 80% of their usual insulin glargine dose.
2. Group 2 patients will contact their own diabetes care physician and follow those
recommendations for the dose.
3. Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose.
Which of those three percentages will be determined by the midpoint of the patient's
usual self-reported fasting blood sugar (FBS) range and whether the patients is also
taking a rapid-acting insulin.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Scheduled for Surgical Procedure
- Self Management of Diabetes
- Currently on Evening Insulin Glargine prescribed by Primary Care Physician
- Age 18 or over
- Able to Communicate Clearly over the Phone
- Pre-screened by Anesthesia Department > 48 hours prior to Surgery
Exclusion Criteria:
- On Glucocorticoid Medication
- On Insulin Glargine Dual Dosing or Sliding Scale Regimen
- History of Hypoglycemia Unawareness
- Pregnancy or Lactating Female
- On Insulin Glargine for < 3 months
Locations and Contacts
William Beaumont Hospital, Royal Oak, Michigan 48073, United States
William Beaumont Hospital, Troy, Michigan 48085, United States
Additional Information
Starting date: October 2005
Last updated: November 1, 2012
|
